Hubbry Logo
PhenytoinPhenytoinMain
Open search
Phenytoin
Community hub
Phenytoin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Phenytoin
Phenytoin
Phenytoin
View on Wikipedia
from Wikipedia

Phenytoin
Structural formula of phenytoin
Ball-and-stick model of the phenytoin molecule
Clinical data
Pronunciation/fəˈnɪtoʊɪn, ˈfɛnɪtɔɪn/
Trade namesDilantin, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa682022
License data
Pregnancy
category
  • AU: D
  • Toxic to reproduction
Routes of
administration		By mouth, intravenous
Drug classAnticonvulsant
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability70–100% (oral), 24.4% (rectal)
Protein binding95%[3]
MetabolismLiver
Onset of action10–30 min (intravenous)[4]
Elimination half-life10–22 hours[3]
Duration of action24 hours[4]
ExcretionUrinary (23–70%), bile[5]
Identifiers
  • 5,5-diphenylimidazolidine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.298 Edit this at Wikidata
Chemical and physical data
FormulaC15H12N2O2
Molar mass252.273 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
  • InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19) ☒N
  • Key:CXOFVDLJLONNDW-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Phenytoin (PHT), sold under the brand name Dilantin among others,[1] is an anti-seizure medication.[3] It is useful for the prevention of tonic-clonic seizures (also known as grand mal seizures) and focal seizures, but not absence seizures.[3] The intravenous form, fosphenytoin, is used for status epilepticus that does not improve with benzodiazepines.[3] It may also be used for certain heart arrhythmias or neuropathic pain.[3] It can be taken intravenously or by mouth.[3] The intravenous form generally begins working within 30 minutes and is effective for roughly 24 hours.[4] Blood levels can be measured to determine the proper dose.[3]

Common side effects include nausea, stomach pain, loss of appetite, poor coordination, increased hair growth, and enlargement of the gums.[3] Potentially serious side effects include sleepiness, self harm, liver problems, bone marrow suppression, low blood pressure, toxic epidermal necrolysis,[3] and atrophy of the cerebellum.[6][7][8] There is evidence that use during pregnancy results in abnormalities in the baby.[3] It appears to be safe to use when breastfeeding.[3] Alcohol may interfere with the medication's effects.[3]

Phenytoin was first made in 1908 by the German chemist Heinrich Biltz and found useful for seizures in 1936.[9][10] It is on the World Health Organization's List of Essential Medicines.[11] Phenytoin is available as a generic medication.[12] In 2020, it was the 260th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[13][14]

Medical uses

[edit]

Seizures

[edit]
  • Tonic-clonic seizures: Mainly used in the prophylactic management of tonic-clonic seizures with complex symptomatology (psychomotor seizures). A period of 5–10 days of dosing may be required to achieve anticonvulsant effects.[citation needed]
  • Focal seizures: Mainly used to protect against the development of focal seizures with complex symptomatology (psychomotor and temporal lobe seizures). Also effective in controlling focal seizures with autonomic symptoms.[citation needed]
  • Absence seizures: Not used in treatment of pure absence seizures due to risk for increasing frequency of seizures. However, can be used in combination with other anticonvulsants during combined absence and tonic-clonic seizures.[citation needed]
  • Seizures during surgery: A 2018 meta-analysis found that early antiepileptic treatment with either phenytoin or phenobarbital reduced the risk of seizure in the first week after neurosurgery for brain tumors.[15]
  • Status epilepticus: Considered after failed treatment using a benzodiazepine due to slow onset of action.[16]

Though phenytoin has been used to treat seizures in infants, as of 2023, its effectiveness in this age group has been evaluated in only one study. Due to the lack of a comparison group, the evidence is inconclusive.[17]

Other

[edit]

Special considerations

[edit]
  • Phenytoin has a narrow therapeutic index. Its therapeutic range for both anticonvulsant and antiarrhythmic effect is 10–20 μg/mL.
  • Avoid giving intramuscular formulation unless necessary due to skin cell death and local tissue destruction.
  • Elderly patients may show earlier signs of toxicity.
  • In the obese, ideal body weight should be used for dosing calculations.
  • Pregnancy: Pregnancy category D due to risk of fetal hydantoin syndrome and fetal bleeding. However, optimal seizure control is very important during pregnancy so drug may be continued if benefits outweigh the risks. Due to decreased drug concentrations as a result of plasma volume expansion during pregnancy, dose of phenytoin may need to be increased if only option for seizure control.
  • Breastfeeding: The manufacturer does not recommend breastfeeding since low concentrations of phenytoin are excreted in breast milk.[20]
  • Liver disease: Do not use oral loading dose. Consider using decreased maintenance dose.
  • Kidney disease: Do not use oral loading dose. Can begin with standard maintenance dose and adjust as needed.
  • Intravenous use is contraindicated in patients with sinus bradycardia, sinoatrial block, second- or third-degree atrioventricular block, Stokes-Adams syndrome, or hypersensitivity to phenytoin, other hydantoins or any ingredient in the respective formulation.

Side effects

[edit]

Common side effects include nausea, stomach pain, loss of appetite, poor coordination, increased hair growth, and enlargement of the gums. Potentially serious side effects include sleepiness, self harm, liver problems, bone marrow suppression, low blood pressure, and toxic epidermal necrolysis. There is evidence that use during pregnancy results in abnormalities in the baby. Its use appears to be safe during breastfeeding. Alcohol may interfere with the medication's effects.[3]

Heart and blood vessels

[edit]

Severe low blood pressure and abnormal heart rhythms can be seen with rapid infusion of IV phenytoin. IV infusion should not exceed 50 mg/min in adults or 1–3 mg/kg/min (or 50 mg/min, whichever is slower) in children. Heart monitoring should occur during and after IV infusion. Due to these risks, oral phenytoin should be used if possible.[21]

Neurological

[edit]

At therapeutic doses, phenytoin may produce nystagmus on lateral gaze. At toxic doses, patients experience vertical nystagmus, double vision, sedation, slurred speech, cerebellar ataxia, and tremor.[22] If phenytoin is stopped abruptly, this may result in increased seizure frequency, including status epilepticus.[21][20]

Phenytoin may accumulate in the cerebral cortex over long periods of time which can cause atrophy of the cerebellum. The degree of atrophy is related to the duration of phenytoin treatment and is not related to dosage of the medication.[23]

Phenytoin is known to be a causal factor in the development of peripheral neuropathy.[24]

Blood

[edit]

Folate is present in food in a polyglutamate form, which is then converted into monoglutamates by intestinal conjugase to be absorbed by the jejunum. Phenytoin acts by inhibiting this enzyme, thereby causing folate deficiency, and thus megaloblastic anemia.[25] Other side effects may include: agranulocytosis,[26] aplastic anemia,[27] decreased white blood cell count,[28] and a low platelet count.[29]

Pregnancy

[edit]

Phenytoin is a known teratogen, since children exposed to phenytoin are at a higher risk of birth defects than children born to women without epilepsy and to women with untreated epilepsy.[30][31] The birth defects, which occur in approximately 6% of exposed children, include neural tube defects, heart defects and craniofacial abnormalities, including broad nasal bridge, cleft lip and palate, and smaller than normal head.[31][32] The effect on IQ cannot be determined as no study involves phenytoin as monotherapy, however poorer language abilities and delayed motor development may have been associated with maternal use of phenytoin during pregnancy.[30] This syndrome resembles the well-described fetal alcohol syndrome.[33] and has been referred to as "fetal hydantoin syndrome". Some recommend avoiding polytherapy and maintaining the minimal dose possible during pregnancy, but acknowledge that current data fails to demonstrate a dose effect on the risk of birth defects.[30][31] Data now being collected by the Epilepsy and Antiepileptic Drug Pregnancy Registry may one day answer this question definitively.

Cancer

[edit]

There is no good evidence to suggest that phenytoin is a human carcinogen.[34][35] However, lymph node abnormalities have been observed, including malignancies.[36]

Mouth

[edit]

Phenytoin has been associated with drug-induced gingival enlargement (overgrowth of the gums), probably due to above-mentioned folate deficiency; indeed, evidence from a randomized controlled trial suggests that folic acid supplementation can prevent gingival enlargement in children who take phenytoin.[37] Plasma concentrations needed to induce gingival lesions have not been clearly defined. Effects consist of the following: bleeding upon probing, increased gingival exudate, pronounced gingival inflammatory response to plaque levels, associated in some instances with bone loss but without tooth detachment.

Skin

[edit]

Hypertrichosis, Stevens–Johnson syndrome, purple glove syndrome, rash, exfoliative dermatitis, itching, excessive hairiness, and coarsening of facial features can be seen in those taking phenytoin.

Phenytoin therapy has been linked to the life-threatening skin reactions Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These conditions are significantly more common in patients with a particular HLA-B allele, HLA-B*1502.[38] This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians.

Phenytoin is primarily metabolized to its inactive form by the enzyme CYP2C9. Variations within the CYP2C9 gene that result in decreased enzymatic activity have been associated with increased phenytoin concentrations, as well as reports of drug toxicities due to these increased concentrations.[39] The U.S. Food and Drug Administration (FDA) notes on the phenytoin drug label that since strong evidence exists linking HLA-B*1502 with the risk of developing SJS or TEN in patients taking carbamazepine, consideration should be given to avoiding phenytoin as an alternative to carbamazepine in patients carrying this allele.[40]

Immune system

[edit]

Phenytoin has been known to cause drug-induced lupus.[41]

Phenytoin is also associated with induction of reversible IgA deficiency.[42]

Psychological

[edit]

Phenytoin may increase risk of suicidal thoughts or behavior. People on phenytoin should be monitored for any changes in mood, the development or worsening depression, and/or any thoughts or behavior of suicide.[20]

Bones

[edit]

Chronic phenytoin use has been associated with decreased bone density and increased bone fractures. Phenytoin induces metabolizing enzymes in the liver. This leads to increased metabolism of vitamin D, thus decreased vitamin D levels. Vitamin D deficiency, as well as low calcium and phosphate in the blood cause decreased bone mineral density.[20]

Interactions

[edit]

Phenytoin is an inducer of the CYP3A4 and CYP2C9 families of the P450 enzyme responsible for the liver's degradation of various drugs.[43]

A 1981 study by the National Institutes of Health showed that antacids administered concomitantly with phenytoin "altered not only the extent of absorption but also appeared to alter the rate of absorption. Antacids administered in a peptic ulcer regimen may decrease the AUC of a single dose of phenytoin. Patients should be cautioned against concomitant use of antacids and phenytoin."[44]

Warfarin and trimethoprim increase serum phenytoin levels and prolong the serum half-life of phenytoin by inhibiting its metabolism. Consider using other options if possible.[45]

In general, phenytoin can interact with the following drugs:[citation needed]

Pharmacology

[edit]

Mechanism of action

[edit]
The mechanism of action of phenytoin sodium. Sodium channels are: 1) Closed 2) Open 3) Inactive (phenytoin effect)

Phenytoin is believed to protect against seizures by causing voltage-dependent block of voltage gated sodium channels.[46] This blocks sustained high frequency repetitive firing of action potentials. This is accomplished by reducing the amplitude of sodium-dependent action potentials through enhancing steady-state inactivation. Sodium channels exist in three main conformations: the resting state, the open state, and the inactive state.

Phenytoin binds preferentially to the inactive form of the sodium channel. Because it takes time for the bound drug to dissassociate from the inactive channel, there is a time-dependent block of the channel. Since the fraction of inactive channels is increased by membrane depolarization as well as by repetitive firing, the binding to the inactive state by phenytoin sodium can produce voltage-dependent, use-dependent and time-dependent block of sodium-dependent action potentials.[47]

The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited.[48] Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses which prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of generalized tonic-clonic seizures.[21]

Pharmacokinetics

[edit]

Phenytoin elimination kinetics show mixed-order, non-linear elimination behaviour at therapeutic concentrations. Where phenytoin is at low concentration it is cleared by first order kinetics, and at high concentrations by zero order kinetics. A small increase in dose may lead to a large increase in drug concentration as elimination becomes saturated. The time to reach steady state is often longer than 2 weeks.[49][50][51][52]

History

[edit]

Phenytoin (diphenylhydantoin) was first synthesized by German chemist Heinrich Biltz in 1908.[53] Biltz sold his discovery to Parke-Davis, which did not find an immediate use for it. In 1938, other physicians, including H. Houston Merritt and Tracy Putnam, discovered phenytoin's usefulness for controlling seizures, without the sedative effects associated with phenobarbital.[54]

According to Goodman and Gilman's Pharmacological Basis of Therapeutics:

In contrast to the earlier accidental discovery of the antiseizure properties of potassium bromide and phenobarbital, phenytoin was the product of a search among nonsedative structural relatives of phenobarbital for agents capable of suppressing electroshock convulsions in laboratory animals.[55]

It was approved by the FDA in 1953 for use in seizures.[citation needed]

Jack Dreyfus, founder of the Dreyfus Fund, became a major proponent of phenytoin as a means to control nervousness and depression when he received a prescription for Dilantin in 1966. He has claimed to have supplied large amounts of the drug to Richard Nixon throughout the late 1960s and early 1970s, although this is disputed by former White House aides[56] and Presidential historians.[57] Dreyfus' experience with phenytoin is outlined in his book, A Remarkable Medicine Has Been Overlooked.[58] Despite more than $70 million in personal financing, his push to see phenytoin evaluated for alternative uses has had little lasting effect on the medical community. This was partially because Parke-Davis was reluctant to invest in a drug nearing the end of its patent life, and partially due to mixed results from various studies.[citation needed]

In 2008, the drug was put on the FDA's Potential Signals of Serious Risks List to be further evaluated for approval. The list identifies medications with which the FDA has identified potential safety issues, but has not yet identified a causal relationship between the drug and the listed risk. To address this concern, the Warnings and Precautions section of the labeling for Dilantin injection was updated to include additional information about Purple glove syndrome in November 2011.[59]

Society and culture

[edit]

Economics

[edit]

Phenytoin is available as a generic medication.[12]

Since September 2012, the marketing licence in the UK has been held by Flynn Pharma Ltd, of Dublin, Ireland, and the product, although identical, has been called Phenytoin Sodium xxmg Flynn Hard Capsules. (The xxmg in the name refers to the strength—for example "Phenytoin sodium 25 mg Flynn Hard Capsules").[60] The capsules are still made by Pfizer's Goedecke subsidiary's plant in Freiburg, Germany, and they still have Epanutin printed on them.[61] After Pfizer's sale of the UK marketing licence to Flynn Pharma, the price of a 28-pack of 25 mg phenytoin sodium capsules marked Epanutin rose from 66p (about $0.88) to £15.74 (about $25.06). Capsules of other strengths also went up in price by the same factor—2,384%,[62] costing the UK's National Health Service an extra £43 million (about $68.44 million) a year.[63] The companies were referred to the Competition and Markets Authority (CMA) who found that they had exploited their dominant position in the market to charge "excessive and unfair" prices.[64]

The CMA imposed a record £84.2 million fine on the manufacturer Pfizer, and a £5.2 million fine on the distributor Flynn Pharma and ordered the companies to reduce their prices.[65]

Brand names

[edit]

Phenytoin is marketed under many brand names worldwide.[1]

In the US, Dilantin is marketed by Viatris after Upjohn was spun off from Pfizer.[66][67][68]

Research

[edit]

Tentative evidence suggests that topical phenytoin is useful in wound healing in people with chronic skin wounds.[69][70] A meta-analysis also supported the use of phenytoin in managing various ulcers.[71] Phenytoin is incorporated into compounded medications to optimize wound treatment, often in combination with misoprostol.[72][73]

Some clinical trials have explored whether phenytoin can be used as neuroprotector in multiple sclerosis.[74]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Phenytoin

View on Grokipedia
from Grokipedia
Phenytoin, chemically known as 5,5-diphenylhydantoin, is an primarily indicated for the management of , including generalized tonic-clonic seizures, complex partial seizures, and , as well as for preventing and treating seizures during or following . First synthesized in 1908 by German chemist Heinrich Biltz as a derivative, its potent properties were discovered in the late 1930s through systematic testing by researchers H. Houston Merritt and Tracy Putnam, who identified it as superior to existing therapies like for controlling major motor seizures without excessive sedation. Phenytoin exerts its therapeutic effects by prolonging the inactive state of voltage-gated sodium channels in neuronal membranes, thereby stabilizing hyperexcitable cells and inhibiting the propagation of seizure discharges. Marketed under brand names such as Dilantin, it revolutionized treatment upon its introduction in 1938 but is characterized by nonlinear , a narrow , and potential for significant adverse effects including gingival , , and hematologic disturbances, necessitating careful monitoring of serum levels.

Therapeutic Applications

Epilepsy and Seizure Management

Phenytoin is indicated for the management of generalized tonic-clonic seizures and complex partial seizures in epilepsy patients. It demonstrates efficacy in controlling these seizure types through stabilization of neuronal membranes via voltage-gated sodium channel modulation, reducing the frequency and severity of recurrent episodes in clinical practice. Early empirical testing in the 1930s by H. Houston Merritt and Tracy J. Putnam involved administering the compound to patients with refractory epilepsy unresponsive to prior therapies like phenobarbital, yielding marked reductions in seizure frequency and establishing its role as a foundational anticonvulsant introduced clinically in 1938. In , phenytoin functions as a second-line intravenous agent after initial administration, where it is loaded at 15-20 mg/kg to achieve rapid therapeutic concentrations. Randomized trials, including the Established Status Epilepticus Treatment Trial (ESETT), have shown cessation rates of approximately 50% within 20 minutes post-infusion, with rates up to 64-70% reported in pediatric and adult cohorts across multiple studies evaluating its prompt effects. 30724-X/fulltext) These outcomes underscore its utility in terminating prolonged when first-line options fail, though infusion rates must be controlled at 50 mg/min or less to mitigate cardiovascular risks. Long-term relies on oral , typically initiated at 300 mg daily and titrated to 300-400 mg per day in divided doses for adults, with adjustments guided by individual due to its zero-order elimination kinetics. Therapeutic monitoring targets plasma levels of 10-20 mcg/mL, as levels below this threshold correlate with increased breakthrough risk, while steady-state achievement requires 7-10 days post-dose stabilization. Regular level assessments, particularly in refractory cases, enable dose optimization to sustain control, with empirical data from chronic users confirming sustained efficacy in preventing recurrence when levels are maintained within range.

Non-Epileptic Indications

Intravenous phenytoin has been employed for -induced arrhythmias, particularly ventricular ectopy and tachydysrhythmias, due to its blockade of voltage-gated sodium channels, which stabilizes cardiac membranes and suppresses ectopic firing without significantly impairing atrioventricular conduction. Early experimental work in dogs during the demonstrated its ability to control ventricular arrhythmias post-myocardial , leading to clinical application by 1958 for terminating refractory in humans. A confirms efficacy in digitalis toxicity-associated arrhythmias and premature ventricular contractions, though contemporary guidelines favor digoxin-specific antibodies and correction as primary interventions, relegating phenytoin to adjunctive or historical roles amid risks of and narrow . Phenytoin is used off-label for , especially acute crises, where intravenous loading doses achieve rapid analgesia by modulating neuronal hyperexcitability and reducing ectopic discharges in damaged nerves. Retrospective case series report pain relief in over 80% of refractory cases within hours, with effects persisting days post-infusion, supporting its role since initial observations in 1941. However, evidence derives largely from small, non-randomized studies rather than robust randomized controlled trials, positioning as the first-line agent due to superior RCT-backed efficacy and oral tolerability, while phenytoin's use is reserved for carbamazepine failures or intravenous needs. For broader , phenytoin exhibits limited empirical support, with topical formulations (5-10% cream) showing effects in small cohorts by local inhibition, absent systemic adverse events. Oral or intravenous applications lack large-scale RCTs confirming superiority over established options like gabapentinoids, and mechanistic benefits in ectopic firing are outweighed by pharmacokinetic variability and toxicity risks. Investigational uses include alcohol withdrawal, but randomized trials demonstrate no benefit over in preventing recurrence, with 21% rates comparable to controls during high-risk periods. Similarly, roles in lack supportive data, as phenytoin more commonly induces hyperkinetic movements via modulation rather than alleviating them. These applications remain unsupported by causal evidence favoring first-line alternatives like benzodiazepines for withdrawal or antagonists for chorea.

Dosing and Special Considerations

Phenytoin dosing requires careful adjustment due to its nonlinear , characterized by zero-order elimination at therapeutic plasma concentrations, where small increases in dose can lead to disproportionate rises in serum levels because hepatic metabolism becomes saturated. Therapeutic monitoring of serum levels (typically targeting total phenytoin 10-20 mcg/mL or unbound 1-2 mcg/mL) is essential to guide adjustments and prevent . For acute management of in adults, an intravenous of 15-20 mg/kg is recommended, administered at a rate not exceeding 50 mg/min (or 1-3 mg/kg/min in ) to minimize cardiovascular risks such as and arrhythmias associated with rapid infusion and the vehicle in parenteral formulations. Maintenance dosing typically begins 12-24 hours post-loading at 3-5 mg/kg/day (or 100 mg IV/PO every 6-8 hours), titrated based on clinical response and levels, with oral transition preferred once feasible. In special populations, dosing must account for altered . Elderly patients often exhibit reduced clearance, necessitating initial lower maintenance doses (e.g., starting at 3 mg/kg/day) and more frequent due to potential declines in hepatic function and protein binding. Patients with hepatic or renal impairment require dose reductions (e.g., 10-25% lower) and monitoring of unbound phenytoin fractions, as or can elevate free drug levels despite normal total concentrations. Formulation choices impact administration safety. Oral capsules provide extended-release options for chronic use but exhibit variable ; intravenous phenytoin, solubilized with 40% and adjusted to pH 12, heightens cardiovascular risks during infusion and is incompatible with many fluids. , a water-soluble convertible to phenytoin, avoids -related toxicity, allows faster infusion rates (up to 150 mg PE/min), and supports intramuscular use when IV access is limited.

Clinical Evidence and Efficacy

Effectiveness in Acute and Chronic Seizure Control

In the treatment of benzodiazepine-refractory , intravenous fosphenytoin (a of phenytoin) demonstrates efficacy as a second-line agent, achieving resolution of clinically evident seizures and improved mental status within 60 minutes in 45.6% of patients across adults and children, according to the double-blind Established Status Epilepticus Treatment Trial (ESETT) conducted from 2015 to 2017 and reported in 2019. Similarly, the open-label EcLiPSE trial, involving pediatric patients with convulsive , reported phenytoin terminating seizures in 64% of cases as second-line therapy, with median time to cessation around 22 minutes from infusion start.30724-X/fulltext) These randomized controlled trials highlight phenytoin's role in acute seizure termination, though outcomes vary by patient factors such as etiology and prior benzodiazepine responsiveness. For chronic management, phenytoin effectively controls generalized tonic-clonic and focal s in responsive patients by stabilizing neuronal membranes via blockade, with efficacy tied to maintaining total plasma concentrations of 10-20 /mL. Subtherapeutic levels below 10 /mL correlate with inadequate suppression and treatment failure, often necessitating dose adjustments or to optimize outcomes. Long-term cohort observations indicate that while initial responders experience substantial frequency reductions, a subset develops pharmacoresistance, attributed partly to autoinduction of or progression rather than tolerance per se. Pharmacokinetic variability influences chronic efficacy, with genetic polymorphisms in (primary metabolizer) and (secondary) explaining up to 25-50% reduced in variant carriers (*2 or *3 alleles), leading to challenges in achieving stable therapeutic levels without toxicity. Loss-of-function variants predominantly risk supratherapeutic concentrations, but ultra-rapid or non-compliance can yield subtherapeutic states, contributing to non-response in 20-30% of cases where levels fail to correlate with clinical benefit despite adherence. Population studies underscore the need for genotype-guided dosing in diverse cohorts to mitigate such variability.

Comparative Efficacy with Alternatives

In benzodiazepine-refractory convulsive , phenytoin's cessation rate is approximately 50%, lower than alternatives such as (around 76%) and (around 69%), according to a 2013 of published studies evaluating five antiepileptic drugs.00349-X/fulltext) A more recent 2024 network ranked highest for control (98%), followed by (61%) and fosphenytoin (a of phenytoin) at 40%, underscoring phenytoin's relatively lower in this context among second-line options. However, some report comparable cessation rates between and phenytoin/fosphenytoin (odds ratio near 1.0), though shows a slight edge in pooled relative risk (1.10) for resolution in certain analyses.00242-9/fulltext) Pediatric trials further highlight limitations; a 2019 prospective study found parenteral superior to phenytoin for terminating convulsive , with higher success rates and faster resolution, supporting phenobarbital's preference in this population despite phenytoin's historical use. In adults, randomized evidence from the 2019 Established Treatment Trial (ESETT) showed no significant differences in efficacy among , fosphenytoin, and for benzodiazepine- cases, but phenytoin's narrower therapeutic window and loading challenges contribute to critiques of its routine prioritization over broader-spectrum agents. For chronic epilepsy management, phenytoin's long-term retention rates are lower than newer antiepileptics, with 5-year retention at 55% compared to 69% for and 75% for , primarily due to tolerability issues rather than inefficacy alone. This disparity reflects evidence favoring alternatives in refractory , where phenytoin's enzyme-inducing properties and side effect profile lead to higher discontinuation, prompting recommendations to reserve it for specific scenarios like focal seizures rather than first-line use. Despite these comparisons, phenytoin remains effective in select cases, but meta-analytic data indicate over-reliance persists amid growing evidence for superior options in both acute and maintenance therapy.00215-1/fulltext)

Prophylactic Use and Limitations

Phenytoin has been employed prophylactically in patients with severe (TBI) to mitigate early post-traumatic s occurring within the first 7 days post-injury. Randomized controlled trials, including a multicenter study of 404 patients, confirm that phenytoin significantly reduces the incidence of these early s compared to , with efficacy attributed to its rapid loading and short-term suppression of epileptiform activity. However, this benefit is confined to the initial week; multiple analyses, including evidence-based reviews, indicate no reduction in late post-traumatic s beyond 7 days, prompting guidelines to advise against extended prophylaxis solely for late prevention. A 1990 randomized, double-blind trial reported in the New England Journal of Medicine further highlighted limitations, showing phenytoin's protective effect against s dissipates after the first week, with prolonged administration potentially associated with impaired cognitive recovery, as evidenced by poorer neuropsychological outcomes in treated groups at follow-up assessments. In neurosurgical and TBI contexts, routine extended use remains questionable; a 2022 comparative study of 100 patients found no difference in overall frequency between 7-day and 21-day phenytoin courses, with the longer regimen conferring no additional long-term prophylaxis while elevating risks of adverse effects such as hepatotoxicity and hematologic disturbances. Phenytoin's narrow therapeutic window (10-20 mg/L) exacerbates these limitations, as its zero-order often result in supratherapeutic levels even with standard dosing, necessitating frequent monitoring to avoid without yielding sustained preventive gains over strategies. This profile, combined with comparable alternatives like showing similar short-term efficacy but fewer monitoring demands, underscores a suboptimal cost-benefit ratio for routine phenytoin prophylaxis beyond acute phases, particularly given the absence of mortality or functional outcome improvements in large cohorts.

Safety Profile and Adverse Effects

Common and Dose-Dependent Effects

Phenytoin frequently induces dose-dependent neurological effects, primarily manifesting as at serum concentrations of 20-30 mg/L, with progression to , slurred speech, , tremors, , and at 30-40 mg/L. These symptoms correlate with levels exceeding the therapeutic range of 10-20 mcg/mL and resolve upon dose reduction or discontinuation. Within therapeutic levels, mild sedation or subtle coordination issues may occur but are less pronounced. Chronic administration commonly leads to gingival hyperplasia in 15-50% of patients, characterized by overgrowth of gingival tissue due to phenytoin-stimulated proliferation and synthesis. This effect is more prevalent with prolonged use and poorer , affecting younger patients disproportionately. Other frequent effects include cosmetic changes such as , which is more pronounced in women, and coarsening of facial features from long-term exposure. Phenytoin also induces hepatic enzymes that accelerate metabolism, resulting in deficiency and associated or loss in up to 50% of long-term users. is similarly common, contributing to potential hematological or neurological sequelae without direct dose correlation. These metabolic disturbances underscore the need for monitoring in extended therapy.

Serious Systemic Risks

Phenytoin carries risks of rare but potentially fatal hematologic toxicities, including and . has been documented in case reports and epidemiological studies, with antiepileptic drugs like phenytoin associated with a multifold increased compared to non-use, though absolute incidence remains low at approximately 1 in 10,000 to 50,000 exposures based on clinical observations and data. , an idiosyncratic reaction involving severe ( <0.5 × 10^9/L), occurs rarely, with drug-induced cases overall estimated at 1.6 to 9 per million annually, and phenytoin implicated in isolated reports typically within weeks of initiation. Hepatic toxicity manifests primarily in the context of hypersensitivity reactions, often with concurrent rash, and can progress to fulminant failure. Rash accompanies approximately 5% of new phenytoin initiations among aromatic anticonvulsants, with hepatic involvement elevating severity in a subset of cases. Severe hepatotoxicity requires immediate discontinuation, as it correlates with multi-organ hypersensitivity syndromes. Intravenous phenytoin administration poses cardiovascular risks, including hypotension, bradycardia, and arrhythmias, particularly with rapid infusion rates exceeding 50 mg per minute. These effects stem largely from the propylene glycol vehicle rather than the active drug, potentially causing myocardial depression and asystole in extreme cases. Slower infusion and cardiac monitoring mitigate these hazards. Immunologic hypersensitivity, notably drug reaction with eosinophilia and systemic symptoms (DRESS), affects roughly 1 in 5,000 to 10,000 phenytoin exposures, presenting with fever, widespread rash, eosinophilia, and visceral organ damage such as hepatitis or nephritis. Mortality approaches 10% in confirmed cases, underscoring the need for prompt recognition and drug cessation. Genetic factors, including HLA alleles, may predispose certain populations.

Overdose and Toxicity Management

Phenytoin exhibits saturable hepatic metabolism, following zero-order kinetics above approximately 10 mcg/mL, which results in nonlinear elimination and disproportionate rises in serum concentrations from small dose increases, predisposing to acute toxicity even within therapeutic dosing ranges. This pharmacokinetic property, combined with its narrow therapeutic index (typically 10-20 mcg/mL), heightens overdose risk, particularly in scenarios involving autoinduction during initiation or formulation changes. Elderly patients face elevated susceptibility due to reduced metabolic capacity and lower serum albumin, which decreases protein binding and elevates free drug fractions; polypharmacy further exacerbates this by altering clearance or compliance. Acute overdose manifests primarily as neurotoxicity, with symptoms correlating to serum levels: mild nystagmus and ataxia at 20-30 mcg/mL, progressing to dysarthria, lethargy, and cerebellar dysfunction at 30-40 mcg/mL, and severe coma, hypotension, or respiratory depression above 40 mcg/mL. Cardiovascular effects, such as arrhythmias or hypotension, occur more frequently with rapid intravenous administration rather than oral overdose but can arise in massive ingestions due to sodium channel blockade. Seizures paradoxically may emerge in toxicity, contrasting phenytoin's antiseizure role. Management prioritizes supportive care, including airway protection, hemodynamic stabilization, and seizure control with benzodiazepines or alternative anticonvulsants, as no specific antidote exists. Gastrointestinal decontamination via single- or multiple-dose activated charcoal (1 g/kg initially, then 0.5 g/kg every 4-6 hours) enhances elimination through gut dialysis, given phenytoin's delayed absorption and slowed motility; this is most effective if initiated early post-ingestion. Extracorporeal removal like hemodialysis is generally ineffective owing to >90% protein binding, though charcoal hemoperfusion may accelerate clearance in life-threatening cases unresponsive to supportive measures; forced alkaline lacks efficacy and is not recommended. Serum levels guide ongoing monitoring, with free phenytoin assays preferred in .

Reproductive and Developmental Concerns

Teratogenicity and Fetal Risks

Phenytoin exposure during the first trimester of is associated with fetal hydantoin syndrome (FHS), a pattern of congenital anomalies including craniofacial dysmorphism (such as , low , and cleft lip/palate), limb (e.g., hypoplastic and digitalized fingertips), growth retardation, and cognitive impairments. The incidence of full FHS is estimated at 5-10% among exposed fetuses, though major malformation rates from pregnancy registries reach 10.5%. North American Antiepileptic Drug (AED) Pregnancy Registry data indicate a malformation prevalence of 4.2% for first-trimester phenytoin monotherapy exposures, compared to 1.1% in unexposed controls, with defects occurring at higher rates than in untreated but comparable to those with or exposure. Risks exhibit dose-dependency, with higher daily doses correlating to elevated malformation rates; exposures exceeding typical maintenance levels (e.g., above 300 mg/day) are linked to increased odds of major congenital anomalies approaching 10% in registry cohorts. Animal models substantiate this via phenytoin-induced pathways, where reactive intermediates generate free radicals, depleting and damaging embryonic proteins, lipids, and DNA, thereby mediating teratogenesis. Long-term neurodevelopmental outcomes include cognitive deficits, with epidemiological studies reporting mean IQ reductions of 5-10 points in phenytoin-exposed offspring compared to unexposed siblings or controls, alongside impairments in performance IQ, full-scale IQ, and visual-motor integration. These effects persist into childhood, independent of frequency, though confounding by maternal severity and polytherapy complicates attribution; no significant IQ differences were noted versus some alternative AEDs like lamotrigine in adjusted analyses. Registry data emphasize that while phenytoin confers specific risks, untreated maternal pose independent threats to fetal oxygenation and development.

Pregnancy, Breastfeeding, and Fertility

Phenytoin is classified as FDA D, signifying positive evidence of human fetal risk from investigational or postmarketing data, though it may be acceptable when benefits outweigh risks, such as in women with refractory where control is critical. Guidelines from epilepsy specialists recommend avoiding phenytoin during when feasible, favoring alternatives like due to its comparatively lower teratogenic profile in monotherapy. For patients unable to discontinue phenytoin, continuation is warranted with close monitoring of maternal plasma levels, as pregnancy-induced pharmacokinetic changes— including up to 20% increased clearance—can elevate frequency if doses are not adjusted. Phenytoin transfers into at concentrations averaging about 18% of maternal serum levels, with reported milk levels of 0.5–1.4 mg/L when maternal serum averages 4.5 mg/L, resulting in low absolute infant exposure. The deems phenytoin compatible with , citing minimal risk to most infants, though vigilance for , poor feeding, or rare hematologic effects is advised, particularly in neonates. Phenytoin exerts no direct substantial effects on in men or women based on available clinical data. However, its induction of hepatic enzymes, particularly , accelerates metabolism of ethinyl and progestins in oral contraceptives, thereby reducing their efficacy and heightening risk; non-hormonal or alternative methods are thus recommended for affected patients.

Pharmacological Properties

Mechanism of Action

Phenytoin exerts its effects primarily through use-dependent blockade of voltage-gated sodium channels (NaV) in neuronal membranes. By preferentially binding to and stabilizing these channels in their inactivated state during sustained , phenytoin prolongs the refractory period and limits the ability of hyperexcitable neurons to generate repetitive action potentials. This mechanism selectively suppresses high-frequency firing patterns characteristic of seizure activity while sparing normal neuronal conduction at therapeutic plasma concentrations of 10-20 mcg/mL. The drug's action is voltage-dependent, with enhanced binding and inhibition occurring at depolarized potentials that mimic those during epileptic bursts, thereby providing state-specific modulation without broadly impairing synaptic transmission under resting conditions. Phenytoin demonstrates minimal direct enhancement of gamma-aminobutyric acid (GABA)-mediated inhibition, distinguishing it from other antiepileptic classes and contributing to its relative efficacy against focal seizures involving rapid, sustained discharges rather than thalamocortical oscillations seen in absence seizures. This selectivity arises from the kinetics of recovery from inactivation, which phenytoin slows in a frequency-dependent manner, effectively filtering pathological hyperactivity.

Pharmacokinetics and Bioavailability

Phenytoin demonstrates oral ranging from 80% to 95%, influenced by characteristics such as and , with absorption primarily occurring in the . Variability arises from factors including gastrointestinal , food intake, and enterohepatic recirculation, which can alter absorption rates and extent. Intravenous administration achieves complete , though the alkaline sodium salt necessitates dilution in normal saline to prevent precipitation in intravenous lines. The drug undergoes nonlinear due to saturable hepatic , primarily mediated by enzymes and , resulting in zero-order elimination kinetics at clinically relevant doses. Plasma half-life varies widely from 7 to 42 hours, averaging 22 hours under steady-state conditions, with elimination rates becoming disproportionately slower as plasma concentrations rise within or above the therapeutic range of 10-20 mg/L. This saturation leads to marked increases in steady-state concentrations for small dose increments, particularly above approximately 7 mg/kg/day, necessitating and individualized dosing adjustments to avoid toxicity. Phenytoin is approximately 90% bound to plasma , with the unbound free fraction responsible for pharmacological effects and potential toxicity. Protein binding decreases in conditions such as , , or hepatic impairment, elevating the free fraction and altering the interpretation of total plasma levels.

Drug Interactions and Contraindications

Major Pharmacokinetic Interactions

Phenytoin acts as a potent inducer of hepatic enzymes, particularly , , and , accelerating the metabolism of substrate drugs and often reducing their plasma concentrations by 30-70% depending on the substrate and duration of co-administration. This induction typically manifests after 1-2 weeks of and persists during chronic use, necessitating dosage adjustments for affected agents to maintain . Co-administration with , a substrate, exhibits a biphasic pharmacokinetic interaction: initial protein displacement transiently elevates free warfarin levels and potentiates anticoagulation, followed by enzyme induction that decreases warfarin concentrations, often requiring a 2- to 5-fold increase in warfarin dosage to sustain therapeutic INR levels (typically 2-3). Phenytoin similarly reduces exposure in oral contraceptives by up to 50% via induction, compromising contraceptive reliability and increasing risks of and , as evidenced by clinical reports of breakthrough and failures. Corticosteroids like undergo accelerated -mediated metabolism, leading to subtherapeutic levels and diminished anti-inflammatory effects, with dose escalations of 1.5-2 times often needed in responsive cases. Drugs inhibiting phenytoin's /2C19-mediated para-hydroxylation or displacing it from (where it is 90% bound) elevate free phenytoin fractions and total levels, risking toxicity at standard doses. Valproic acid displaces phenytoin, raising the free fraction from ~10% to 15-20% and free concentrations by up to twofold through combined displacement and metabolic inhibition, typically requiring 20-50% phenytoin dose reductions and free-level monitoring. competitively inhibits /2C19 at doses ≥800 mg/day, decreasing phenytoin clearance by 20-40% and necessitating similar dose adjustments of 20-50% with serial level checks. Bidirectional interactions complicate polytherapy with other antiepileptics. induces phenytoin metabolism via /2C19 upregulation, reducing steady-state phenytoin levels by 20-40% after 2-4 weeks and often requiring phenytoin dose increases of 20-30%, though initial may transiently elevate levels. inhibits /2C19-mediated phenytoin hydroxylation, increasing total phenytoin concentrations by 50-100% in case reports and studies, with recommendations for 20-50% dose reductions and therapeutic monitoring to avert , , or gingival hyperplasia. These interactions underscore the need for individualized dosing guided by plasma levels, as phenytoin's narrow (10-20 μg/mL total, 1-2 μg/mL free) amplifies risks.

Clinical Management of Interactions

In polytherapy regimens involving phenytoin, (TDM) of serum levels is essential when initiating or discontinuing concomitant medications known to induce or inhibit hepatic enzymes, as such interactions can alter phenytoin concentrations and risk subtherapeutic efficacy or toxicity. Guidelines recommend measuring total phenytoin levels routinely, with free phenytoin assays preferred in patients with ( <3.5 g/dL) or renal impairment, where protein binding is reduced, leading to disproportionate free fraction increases. Levels should be checked 5-7 days after dose changes or new interacting drugs, targeting a therapeutic range of 10-20 mcg/mL for total phenytoin (or 1-2 mcg/mL free). Empirical dose adjustments are often required based on the interacting agent's potency: for strong inducers like or rifampin added to phenytoin therapy, an initial increase of 25-50% in phenytoin dose may be necessary to compensate for accelerated , followed by guided by TDM to maintain efficacy. Conversely, when adding inhibitors such as , phenytoin doses may need reduction by similar increments to prevent accumulation. These adjustments should be individualized, considering patient factors like age and liver function, with serial monitoring to avoid breakthrough seizures from undetectably low levels. Certain combinations warrant avoidance due to high interaction risk; coadministration of phenytoin with delavirdine is contraindicated, as phenytoin's induction of substantially reduces delavirdine exposure, compromising antiretroviral efficacy and risking viral resistance. Similar caution applies to other non-interchangeable therapies where interaction overrides benefits. Patients should receive on interaction risks, including the potential for breakthrough if new medications (prescription, over-the-counter, or ) are introduced without provider consultation, as even brief enzyme induction can drop phenytoin levels below therapeutic thresholds. Emphasis on consistent daily timing of phenytoin doses minimizes absorption variability, which can exacerbate interaction effects in polytherapy. Reporting symptoms like auras or seizure recurrence promptly enables timely TDM and adjustment.

Historical Development

Discovery and Initial Clinical Trials

Phenytoin, chemically 5,5-diphenyl, was first synthesized in 1908 by German chemist Heinrich Biltz at the University of Kiel during systematic investigations into derivatives related to barbiturates. Biltz's work focused on structural analogs of known , but the compound's potential remained unexplored for decades, as initial efforts prioritized sedative properties over seizure control. In the early 1930s, neurologists Tracy J. Putnam and H. Houston Merritt at Presbyterian Hospital developed an empirical screening protocol to identify superior , using maximal electroshock seizures induced in to quantify drug efficacy against tonic-clonic convulsions. Collaborating with , they tested over 400 compounds, including rediscovered samples of Biltz's phenytoin; in models, phenytoin abolished electrically provoked seizures at doses that produced minimal , outperforming bromides (which required high doses with ) and barbiturates (which caused excessive drowsiness). This systematic approach highlighted phenytoin's selective stabilization of neuronal membranes without broad , establishing a causal link between voltage-gated modulation and action through reproducible animal data. Merritt and Putnam initiated human trials in 1937 on patients with refractory , reporting clinical efficacy in 1938 after observing control in a majority of cases unresponsive to prior therapies like bromides or . Phenytoin's lower sedative profile facilitated daytime use, prompting to market it as Diphenylan Sodium (later rebranded Dilantin) starting June 23, 1938, which shifted clinical practice away from dominance and founded the class of antiseizure agents. Formal U.S. approval followed in 1953, validating its safety and efficacy profile from early .

Key Regulatory and Formulation Milestones

In the 1970s, regulatory authorities began emphasizing warnings for phenytoin-associated gingival hyperplasia, a observed in up to 50% of long-term users, and emerging teratogenic risks, including fetal hydantoin syndrome characterized by craniofacial anomalies, limb hypoplasia, and growth retardation, following clinical reports and animal studies linking exposure to malformations. These updates to product labeling reflected accumulating post-marketing data, though initial recognition of gingival overgrowth dated to early clinical trials in . Intravenous phenytoin formulations faced scrutiny for and local irritation stemming from their alkaline pH (around 12) and solvent, prompting recommendations for slower infusion rates (not exceeding 50 mg/min) to mitigate , , and arrhythmias. This led to refinements in administration protocols by the 1980s, emphasizing large-vein delivery and cardiac monitoring. To address these IV limitations, fosphenytoin, a water-soluble convertible to phenytoin, received FDA approval on August 2, 1996, enabling faster and safer parenteral dosing without the solvent-related risks. By the , following expiration, generic phenytoin formulations had achieved market dominance in the and , comprising the majority of prescriptions due to cost advantages over branded Dilantin. In the UK, Flynn Pharma's 2012 acquisition of phenytoin sodium capsules from triggered a pricing controversy, with list prices escalating over 2,600% (from £0.004 to £67 per pack of 100 capsules), inflating NHS expenditures from £2 million to over £50 million annually despite stagnant production costs. The (CMA) investigated for abuse of dominance, imposing fines totaling £94.5 million on and in 2016 (later adjusted to £69.9 million in 2022 after appeals), and mandating price reductions.

Societal, Economic, and Regulatory Aspects

Market Availability and Pricing Dynamics

Phenytoin is widely available as a generic medication in major markets including the , , and other developed economies, with production by multiple manufacturers facilitating broad access for treatment and other indications. The global phenytoin market was valued at approximately USD 1.8 billion in 2023, driven primarily by demand for anti-epileptic therapy despite competition from newer agents. Projections indicate steady growth, potentially reaching around USD 2.5 billion by 2032, reflecting persistent use in resource-limited settings where cost-effective options remain essential, though offset by shifts toward alternatives with fewer interactions. Generic formulations keep daily treatment costs low, typically under USD 1 per day in the US for standard oral doses of 300 mg, with GoodRx discounts enabling prices as low as $8-23 for a 30-day supply of 100 mg extended-release capsules. This affordability stems from generic entry post-patent expiration, minimizing barriers for uninsured or low-income patients, though actual out-of-pocket expenses vary by dosage, formulation (e.g., suspension vs. capsules), and regional pricing. Supply chain vulnerabilities persist, however, as evidenced by ongoing shortages; for instance, Accord Healthcare's phenytoin sodium 100 mg capsules have been long-term out of stock in the UK since at least 2023, with no confirmed resupply date, prompting switches to alternative suppliers and highlighting risks in concentrated manufacturing. Regulatory scrutiny has targeted pricing abuses in transition to generics, exemplified by the UK Competition and Markets Authority (CMA) investigation into phenytoin sodium capsules from 2016 to 2024. The CMA determined that and Pharma exploited market dominance after the original brand delisted from price controls, raising capsule prices over 2,000-fold—from about 2 pence to £5-7 each—resulting in NHS expenditures escalating by more than 10,000% for equivalent volumes compared to pre-2007 levels, totaling excess costs of £100 million over five years. This case underscores failures in oversight during generic shifts, where delisting enabled opportunistic markups absent competition, leading to fines upheld by the Competition Appeal Tribunal in November 2024 despite partial remittals. In the , phenytoin classifies as a Tier 1 generic on most formularies, incurring minimal copays (often $0-10 monthly) and low wholesale acquisition costs, supporting routine prescribing without significant reimbursement hurdles. (TDM), required due to phenytoin's narrow and nonlinear kinetics, imposes additional burdens, with serum level tests averaging $50-100 per assay depending on lab and , potentially adding $200-500 annually for patients needing frequent checks during dose adjustments or interactions. These dynamics favor phenytoin in cost-sensitive scenarios but expose systemic fragilities, as shortages or pricing manipulations elsewhere amplify reliance on stable generic supply chains.

Brand Names, Generics, and Supply Issues

Phenytoin is available under several brand names, including Dilantin (extended-release phenytoin sodium capsules) in the United States and Epanutin in the United Kingdom. Generic versions of phenytoin sodium, in forms such as capsules, tablets, suspensions, and injectables, predominate in most markets following the expiration of early patents decades after its initial FDA approval in 1939. As a narrow therapeutic index drug, phenytoin requires generics to meet stringent FDA criteria, including tighter confidence intervals for pharmacokinetic parameters to minimize risks of subtherapeutic levels or . Despite these standards, clinical reports document bioinequivalence risks from formulation switches, such as from capsules to oral suspension, which can alter nonlinear absorption and lead to reduced serum concentrations, breakthrough seizures, or adverse effects. For instance, patients switching between phenytoin generics have shown increased breakthrough seizure incidence in chart analyses, prompting recommendations for consistent sourcing to maintain steady-state levels. Supply disruptions have intensified these concerns, with ongoing shortages of phenytoin oral suspension reported through 2025; for example, indicated backorders for 125 mg/5 mL bottles extending to December 2025, often necessitating involuntary switches to alternative generics or . organizations, including the Epilepsy Foundation, caution that such substitutions risk loss of seizure control, particularly during transitions from brand to generic, and advise against automatic interchanges without monitoring in vulnerable patients. These issues are amplified in low-resource settings, where limited access to heightens the potential for exacerbated outcomes from formulation variability.

Ongoing Research and Future Directions

Emerging Therapeutic Investigations

Investigations into phenytoin's neuroprotective potential beyond control have yielded mixed results, particularly in (TBI) and cerebral ischemia. While phenytoin has been employed for early posttraumatic prophylaxis in TBI, with guidelines recommending its use to reduce incidence (e.g., 3.4% versus 5.4% for in a 2023 analysis of 1,186 patients), evidence for broader improving functional outcomes remains lacking, as early seizures do not correlate with mortality or disability. Recent 2023 studies have explored combination therapies to enhance outcomes, but no phase III trials have demonstrated sustained efficacy for in these settings. Preliminary research has examined phenytoin's role in remyelination for demyelinating conditions like (MS), based on its sodium channel modulation promoting oligodendrocyte precursor differentiation. A phase 2 trial reported a 30% reduction in retinal layer damage compared to controls, suggesting potential protection, though larger confirmatory studies are absent. In vitro data indicate phenytoin may inhibit replication through effects, akin to its antiarrhythmic properties, but clinical translation has not occurred, with no trials establishing antiviral efficacy . For pediatric , a 2024 open-label (n=100 children) found phenytoin comparable to in achieving control (78% vs. 82% success rate at 24 hours), but phenytoin's higher toxicity profile, including infusion-related adverse events, restricts broader adoption. Expansion to routine use is limited by these safety concerns and the need for further head-to-head trials in diverse etiologies. Topical phenytoin is under evaluation for non-neurologic applications, such as atrophic post-acne scars, with an ongoing trial assessing its fibrogenic effects on scar texture improvement, though results remain preliminary. Over the past decade, prescriptions for phenytoin have declined in favor of newer antiseizure medications (ASMs) such as levetiracetam, which offer broader efficacy across seizure types, linear pharmacokinetics, and reduced need for therapeutic drug monitoring. In Japan, levetiracetam prescriptions increased by 26.7% from fiscal years 2018 to 2021, while phenytoin use decreased amid preferences for agents with fewer drug interactions and lower cognitive side effects. Similarly, in Latin American clinical practice as of 2025, first-generation ASMs like phenytoin accounted for only 3.9% of prescriptions, with third-generation options like levetiracetam comprising 53.7% due to superior tolerability profiles. These shifts reflect evidence that phenytoin's zero-order kinetics and enzyme-inducing properties complicate dosing and increase adverse event risks compared to non-inducers. Discontinuation protocols for phenytoin in seizure-free patients typically commence after 2 years of remission, with gradual tapering over months to minimize . Success rates, defined as sustained seizure freedom, range from 60-70% at 2 years post-withdrawal in adults, though long-term recurrence risks (24-60 months) may exceed 30% for those on older ASMs like phenytoin. risks appear higher following phenytoin withdrawal than with some newer agents, potentially due to its impact on underlying neuronal excitability during taper, as evidenced in older controlled trials where phenytoin rates reached 40-50% within 2 years. Guidelines recommend EEG and clinical assessment prior to discontinuation, with reinstatement of therapy upon recurrence, noting that 80-90% of relapsed patients regain control. Globally, phenytoin use has diminished in prophylaxis settings, such as post-traumatic or postoperative scenarios, where it shows efficacy limited to the first week after injury. has supplanted phenytoin in these contexts for its intravenous availability, lack of cardiovascular effects, and comparable short-term prevention without routine monitoring. Precision medicine approaches, including for and variants, enable early identification of poor metabolizers who require dose adjustments or alternatives, further reducing phenytoin initiation in non-responders. These genetic tools, validated in clinical dosing studies, support tailored therapy to avoid subtherapeutic levels or , aligning with broader trends toward pharmacogenomics-driven ASM selection.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK551520/
  2. https://medlineplus.gov/druginfo/meds/a682022.html
  3. https://pubmed.ncbi.nlm.nih.gov/28083647/
  4. https://pubmed.ncbi.nlm.nih.gov/3547783/
  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/084349s060lbl.pdf
  6. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/084349s087lbl.pdf
  7. https://pubmed.ncbi.nlm.nih.gov/3527690/
  8. https://www.nejm.org/doi/abs/10.1056/NEJMbkrev0809170
  9. https://www.nejm.org/doi/full/10.1056/NEJMoa1905795
  10. https://www.drugs.com/dosage/phenytoin.html
  11. https://pharmacyjoe.com/phenytoin-dosage-adjustment-and-monitoring/
  12. https://emedicine.medscape.com/article/154336-treatment
  13. https://journal.chestnet.org/article/S0096-0217%2816%2930846-9/abstract
  14. https://www.heartlungcirc.org/article/S1443-9506%2820%2930560-6/fulltext
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC9681520/
  16. https://pubmed.ncbi.nlm.nih.gov/32981076/
  17. https://journals.sagepub.com/doi/10.1177/25158163241268880
  18. https://www.clinmedres.org/content/22/4/215
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC5522676/
  20. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1493274/full
  21. https://www.researchgate.net/publication/314141061_Topical_phenytoin_for_the_treatment_of_neuropathic_pain
  22. https://www.remedypublications.com/open-access/rationale-for-the-repositioning-of-phenytoin-as-a-topical-analgesic-for-peripheral-neuropathic-pain-and-a-personalized-and-investigator-driven-development-plan-4706.pdf
  23. https://pubmed.ncbi.nlm.nih.gov/2024792/
  24. https://www.annemergmed.com/article/S0196-0644%2805%2981606-3/fulltext
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC3229798/
  26. https://go.drugbank.com/drugs/DB00252
  27. https://sepia2.unil.ch/pharmacology/drugs/phenytoin/
  28. https://www.sps.nhs.uk/monitorings/phenytoin-monitoring/
  29. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/008762s050%2C010151s038lbl.pdf
  30. https://handbook.ggcmedicines.org.uk/guidelines/central-nervous-system/guideline-for-phenytoin-dose-calculations/
  31. https://globalrph.com/phenytoin-dosing-guidelines/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC2909816/
  33. https://pubmed.ncbi.nlm.nih.gov/8649609/
  34. https://emedicine.medscape.com/article/2090306-overview
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3312854/
  36. https://www.tandfonline.com/doi/full/10.2147/PGPM.S108113
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC5629135/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC7485959/
  39. https://journals.lww.com/md-journal/fulltext/2024/11150/comparative_efficacy_and_safety_of_second_line.50.aspx?context=latestarticles
  40. https://mji.ui.ac.id/journal/index.php/mji/article/view/6685
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC6530138/
  42. https://link.springer.com/article/10.1007/s10309-022-00492-x
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC4295052/
  44. https://pubmed.ncbi.nlm.nih.gov/2115976/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3216189/
  46. https://www.neurology.org/doi/10.1212/01.WNL.0000031432.05543.14
  47. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265932
  48. https://www.nytimes.com/1990/08/23/us/drug-given-for-head-injury-is-ineffective-in-long-term-study-says.html
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC9638559/
  50. https://www.ncbi.nlm.nih.gov/books/NBK482444/
  51. https://www.sciencedirect.com/science/article/pii/S2214751921003066
  52. https://emedicine.medscape.com/article/1076264-overview
  53. https://accessmedicine.mhmedical.com/content.aspx?bookid=685&sectionid=45361080
  54. https://www.aapd.org/globalassets/media/publications/archives/steinberg-03-s1.pdf
  55. https://www.anmfonline.org/wp-content/uploads/2021/06/phenytoin-22032021-5.0.pdf
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC4668458/
  57. https://labeling.pfizer.com/ShowLabeling.aspx?id=9730
  58. https://journals.sagepub.com/doi/pdf/10.1177/201010581302200307
  59. https://www.sciencedirect.com/topics/neuroscience/phenytoin
  60. https://pubmed.ncbi.nlm.nih.gov/16886988/
  61. https://agsjournals.onlinelibrary.wiley.com/doi/full/10.1046/j.1532-5415.2002.50083.x
  62. https://pubmed.ncbi.nlm.nih.gov/1805490/
  63. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.727717/full
  64. https://www.sciencedirect.com/science/article/pii/S1059131119301888
  65. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010151s036lbl.pdf
  66. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1812378
  67. https://www.rch.org.au/clinicalguide/guideline_index/Phenytoin_poisoning/
  68. https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/085060312.pdf
  69. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1108345/full
  70. https://www.jyoungpharm.org/sites/default/files/tmp/JYoungPharm-14-2-253.pdf
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC5623274/
  72. https://emedicine.medscape.com/article/816447-overview
  73. https://wikem.org/wiki/Phenytoin_toxicity
  74. https://medlineplus.gov/ency/article/002533.htm
  75. https://emedicine.medscape.com/article/816447-treatment
  76. https://rarediseases.org/rare-diseases/fetal-hydantoin-syndrome/
  77. https://www.sciencedirect.com/topics/[neuroscience](/page/Neuroscience)/fetal-hydantoin-syndrome
  78. https://my.clevelandclinic.org/health/diseases/fetal-hydantoin-syndrome
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC8015586/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC9185784/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC4816042/
  82. https://www.sciencedirect.com/topics/neuroscience/fetal-hydantoin-syndrome
  83. https://pubmed.ncbi.nlm.nih.gov/7623765/
  84. https://academic.oup.com/toxsci/article/59/1/118/1658851
  85. https://pubmed.ncbi.nlm.nih.gov/1454041/
  86. https://www.sciencedirect.com/science/article/pii/089203629290039D
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC3925312/
  88. https://www.nejm.org/doi/full/10.1056/NEJMoa0803531
  89. https://www.obgproject.com/2017/11/17/antiepileptic-drugs-impact-risk-birth-defects/
  90. https://www.drugs.com/pregnancy/phenytoin.html
  91. https://www.neurology.org/doi/10.1212/WNL.0b013e3181a6b325
  92. https://www.ncbi.nlm.nih.gov/books/NBK501273/
  93. https://publications.aap.org/pediatrics/article/108/3/776/66674/The-Transfer-of-Drugs-and-Other-Chemicals-Into
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC3844381/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC7689629/
  96. https://www.aafp.org/pubs/afp/issues/2019/1115/p599.html
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC5144711/
  98. https://pubmed.ncbi.nlm.nih.gov/2428283/
  99. https://aesnet.org/abstractslisting/atomic-level-simulations-of-phenytoin-binding-to-a-sodium-channel-reveals-several-binding-sites-and-a-potential-structural-basis-of-state-dependent-inhibition
  100. https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.410200202
  101. https://link.springer.com/article/10.1007/BF01243417
  102. https://pediatric.testcatalog.org/show/PNYA
  103. https://go.drugbank.com/articles/A188760
  104. https://pubmed.ncbi.nlm.nih.gov/1261151/
  105. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008762s054%2C010151s041lbl.pdf
  106. https://australianprescriber.tg.org.au/articles/pharmacokinetics-made-easy-9-non-linear-pharmacokinetics.html
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC7691416/
  108. https://pubmed.ncbi.nlm.nih.gov/7013166/
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC7603454/
  110. https://link.springer.com/article/10.1007/s00204-020-02936-7
  111. https://health.ucsd.edu/for-health-care-professionals/anticoagulation-guidelines/warfarin/drug-interactions/
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC1885026/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC1368312/
  114. https://www.neurology.org/doi/10.1212/WNL.30.11.1233
  115. https://pubmed.ncbi.nlm.nih.gov/6777108/
  116. https://pubmed.ncbi.nlm.nih.gov/6839635/
  117. https://pubmed.ncbi.nlm.nih.gov/6617717/
  118. https://www.epilepsy.va.gov/library/druginteractions.pdf
  119. https://www.neurology.org/doi/10.1212/WNL.38.7.1146
  120. https://pubmed.ncbi.nlm.nih.gov/7884016/
  121. https://www.sciencedirect.com/science/article/abs/pii/S0920121100002035
  122. https://accpjournals.onlinelibrary.wiley.com/doi/10.1592/phco.28.11.1391
  123. https://www.droracle.ai/articles/380081/phenytoin-interaction
  124. https://www.medcentral.com/drugs/monograph/4159-382022/phenytoin-oral
  125. https://www.mayoclinic.org/drugs-supplements/phenytoin-oral-route/description/drg-20072875
  126. https://www.epilepsy.com/tools-resources/seizure-medication-list/phenytoin
  127. http://triggered.edina.clockss.org/ServeContent?rft_id=info:doi/10.1124/mi.9.5.1
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC7470169/
  129. https://www.sciencedirect.com/science/article/abs/pii/S0028390819303090
  130. https://www.ccjm.org/content/89/9/488
  131. https://jamanetwork.com/journals/jamaneurology/fullarticle/579474
  132. https://karger.com/books/book/chapter-pdf/2006018/000390591.pdf
  133. https://www.ncbi.nlm.nih.gov/books/NBK560745/
  134. https://pubmed.ncbi.nlm.nih.gov/7075570/
  135. https://www.gov.uk/government/news/70-million-in-fines-for-pharma-firms-that-overcharged-nhs
  136. https://www.gov.uk/cma-cases/investigation-into-the-supply-of-pharmaceutical-products
  137. https://pharmaceutical-journal.com/article/news/pfizer-and-flynn-pharma-fined-69m-for-excessive-pricing-of-epilepsy-drug
  138. https://www.verifiedmarketreports.com/product/phenytoin-market/
  139. https://www.goodrx.com/phenytoin
  140. https://www.epilepsy.org.uk/news/accord-phenytoin-sodium-stock
  141. https://pubmed.ncbi.nlm.nih.gov/2911851/
  142. https://www.dilantin.com/en
  143. https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phenytoin_sodium_ERcap_040298_RV12-14.pdf
  144. https://www.fda.gov/media/162779/download
  145. https://www.neurology.org/doi/10.1212/01.WNL.0000142091.47698.A2
  146. https://pubmed.ncbi.nlm.nih.gov/25295717/
  147. https://medica-musc.researchcommons.org/cgi/viewcontent.cgi?article=1391&context=theses
  148. https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=1160
  149. https://pmc.ncbi.nlm.nih.gov/articles/PMC3018179/
  150. https://journals.lww.com/co-criticalcare/fulltext/2023/12000/the_management_of_severe_traumatic_brain_injury_in.20.aspx
  151. https://pmc.ncbi.nlm.nih.gov/articles/PMC11351448/
  152. https://journals.lww.com/rmr/fulltext/2024/01020/the_potential_role_of_phenytoin_in_myelin.7.aspx
  153. https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/explore-treatments-in-trials/phenytoin
  154. https://pmc.ncbi.nlm.nih.gov/articles/PMC7409030/
  155. https://pubmed.ncbi.nlm.nih.gov/38678766/
  156. https://www.sciencedirect.com/science/article/pii/S1059131124001201
  157. https://pmc.ncbi.nlm.nih.gov/articles/PMC11368275/
  158. https://clinicaltrials.gov/study/NCT06942468
  159. https://www.epilepsybehavior.com/article/S1525-5050%2824%2900330-5/abstract
  160. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1562079/full
  161. https://pmc.ncbi.nlm.nih.gov/articles/PMC12158685/
  162. https://pmc.ncbi.nlm.nih.gov/articles/PMC8075746/
  163. https://www.nejm.org/doi/pdf/10.1056/NEJM198804143181502
  164. https://www.aan.com/Guidelines/home/GetGuidelineContent/996
  165. https://www.pnas.org/doi/10.1073/pnas.0407346102
Add your contribution
Related Hubs
User Avatar
No comments yet.